Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis

Next Previous
X
Search
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HSK 21542 (Primary)
  • Indications Pruritus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Haisco Pharmaceutical Group; Sichuan Haisco Pharmaceutical

    • Most Recent Events

    • 04 Aug 2022 Status changed from recruiting to completed.
    • 04 Aug 2021 Treatment section is updated to 0.80 microg/kg as an additional study dose along with the previously existing ones (0.05 micro g/kg,0.15 micro g/kg, and 0.30 micro g/kg). Thus, the higher dose limit gets increased from 0.30 micro g/kg to 0.80 micro g/kg.
    • 04 Aug 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Oct 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top